Solventum Corporation $SOLV Stock Position Raised by Boston Partners

Boston Partners increased its holdings in shares of Solventum Corporation (NYSE:SOLV) by 9.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,670,757 shares of the company’s stock after acquiring an additional 308,784 shares during the quarter. Boston Partners owned approximately 2.12% of Solventum worth $278,363,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. HB Wealth Management LLC acquired a new stake in shares of Solventum during the 1st quarter worth approximately $249,000. N.E.W. Advisory Services LLC acquired a new position in Solventum during the 1st quarter valued at approximately $49,000. XTX Topco Ltd grew its stake in Solventum by 26.8% during the 1st quarter. XTX Topco Ltd now owns 6,417 shares of the company’s stock worth $488,000 after buying an additional 1,356 shares during the last quarter. Seizert Capital Partners LLC bought a new position in Solventum during the 1st quarter worth $4,452,000. Finally, Natixis Advisors LLC increased its position in Solventum by 5.1% in the first quarter. Natixis Advisors LLC now owns 57,172 shares of the company’s stock worth $4,347,000 after buying an additional 2,766 shares during the period.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SOLV. Wall Street Zen raised shares of Solventum from a “hold” rating to a “buy” rating in a report on Sunday. Wells Fargo & Company lifted their price objective on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. Jefferies Financial Group assumed coverage on shares of Solventum in a research report on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price for the company. Finally, Piper Sandler raised their price target on shares of Solventum from $94.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $85.56.

Solventum Stock Performance

SOLV stock opened at $85.37 on Thursday. The company has a 50-day simple moving average of $73.34 and a 200 day simple moving average of $73.49. The company has a market capitalization of $14.81 billion, a P/E ratio of 9.84, a PEG ratio of 9.05 and a beta of 0.48. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 1.03. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $86.81.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. Solventum’s revenue was up .7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Sell-side analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its board has authorized a share repurchase program on Thursday, November 20th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to purchase up to 7.5% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.